Core Viewpoint - China has implemented restrictions on medical device procurement from European companies in response to similar measures taken by the EU against Chinese firms, indicating a tit-for-tat approach in trade relations [1][5]. Group 1: Government Procurement Measures - The Ministry of Finance announced that for medical device procurement budgets exceeding 45 million RMB, EU companies will be excluded from participation, except for EU-funded enterprises operating in China [2][4]. - The measures specifically target 50 types of medical devices imported from the EU, including both everyday medical instruments and high-end equipment like MRI and X-ray diagnostic devices [4][6]. Group 2: Impact on Domestic Industry - The restrictions are expected to significantly impact high-end medical device manufacturers from the EU, while domestic companies are increasingly filling the market gap with competitive products [5][6]. - Currently, imported medical devices account for 40% of a typical domestic company's business, with only 10% coming from the EU, indicating a shift towards non-EU suppliers [4][6]. Group 3: Future Trends in Domestic Medical Device Market - The domestic medical device industry is projected to see an increase in the replacement rate of imported products, with estimates suggesting that 60% to 80% of devices priced around 5 million RMB can be sourced domestically [7][8]. - The market for high-end medical devices is expected to grow significantly, with projections indicating that by the end of the 14th Five-Year Plan, the market size could reach approximately 2.27 trillion RMB, accounting for 28% of the global market [8][9].

Core Viewpoint - Xiangsheng Medical (688358) announced a cash dividend distribution of 10 CNY per 10 shares, totaling 111,874,753 CNY, which represents 79.62% of the company's net profit attributable to shareholders for the year [1][2][4] Trading Information Summary - On July 8, 2025, Xiangsheng Medical's stock closed at 29.9 CNY, with a slight decline of 0.07%. The turnover rate was 0.93%, with a trading volume of 10,400 shares and a total transaction value of 31,227,400 CNY [1] - The fund flow on the same day showed a net outflow of 480,670 CNY from main funds, accounting for 15.39% of the total transaction value, while retail funds had a net inflow of 598,990 CNY, representing 19.18% of the total [1][4] Company Announcement Summary - Xiangsheng Medical's 2024 annual profit distribution plan includes a cash dividend of 10 CNY per 10 shares (before tax), with the base for distribution being 111,874,753 shares after deducting 249,784 shares held in the repurchase account [1][2] - The dividend distribution will not involve capital reserve conversion into share capital or the issuance of bonus shares. The record date for the dividend is July 14, 2025, and the ex-dividend date and payment date are both set for July 15, 2025 [1][2]

董秘最新回复 截至2025年7月8日收盘，美好医疗(301363)报收于18.17元，下跌0.27%，换手率5.0%，成交量7.81万 手，成交额1.41亿元。 投资者： 董秘您好，1、在2024年年报的行业发展趋势里提到产业技术加快，运用生物、微纳米、信 息、计算机、微加工等高新技术，发展用于微创或无创诊疗的技术和器件，表面改性和组织诱导性生物 医用材料及组织和器官修复器械，以及用于医院及远程诊疗的信息系统。请问贵司产品使用了当下哪些 新技术？2、医疗器械产品向智能化方向转变。请问贵司产品如何体现智能化的应用，比如是否使用机 器人、传感器等提高效率？ 董秘： 尊敬的投资者，您好！公司已预约于2025年8月19日披露2025年半年度报告。感谢您对公司的关 注！ 当日关注点 交易信息汇总：7月8日主力资金净流出706.11万元，而散户资金净流入591.99万元。 交易信息汇总 董秘： 尊敬的投资者，您好！技术应用方面。公司构建了基于通用技术模块化复用与专用技术纵深攻 关的开放式研发创新平台。一方面，基于长期服务全球医疗器械头部客户积累的技术基础，公司研发团 队将医疗器械组件及产品的开发技术、塑胶和液态硅胶精密模 ...

Core Points - The document outlines the procedures and regulations for the resignation of directors and senior management at Yingke Medical Technology Co., Ltd, aiming to maintain corporate governance stability and protect the rights of the company and its shareholders [1][2]. Chapter Summaries Chapter 1: General Provisions - The regulations are established based on relevant laws and the company's articles of association to standardize the resignation process of directors and senior management [1]. Chapter 2: Resignation Circumstances and Procedures - Directors can resign before their term ends by submitting a written resignation report, which becomes effective upon receipt by the company, and the company must disclose this within two trading days [2]. - If a director resigns and it results in the board falling below the legal minimum number of members, the director must continue to fulfill their duties until a new director is appointed [2]. - The company must complete the election of a new director within sixty days after a resignation to ensure compliance with legal and regulatory requirements [2]. - Senior management can also resign before their term ends, with specific procedures outlined in their labor contracts [2]. Chapter 3: Handover Procedures and Obligations - Resigning directors and senior management must complete handover procedures within five working days after their resignation, including transferring company seals and all relevant documents [3]. - If there are outstanding public commitments, the company can require a written fulfillment plan from the resigning personnel [3]. Chapter 4: Management of Shares Held by Resigning Directors and Senior Management - Resigning directors and senior management are prohibited from transferring their shares within six months of resignation [4]. - There are restrictions on the amount of shares that can be sold during their term and after resignation, ensuring compliance with relevant regulations [4]. Chapter 5: Accountability Mechanism - The board will review and determine accountability measures if a resigning director or senior management fails to fulfill commitments or obligations [5]. - Individuals can appeal the board's decisions regarding accountability within fifteen days [5]. Chapter 6: Supplementary Provisions - Any matters not covered by these regulations or conflicting with national laws will be governed by the relevant laws and the company's articles of association [6].

英科医疗科技股份有限公司 章 程 二〇二五年七月 目 录 第一章 总 则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共 和国证券法》（以下简称《证券法》）和其他有关规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司（以下 简称"公司"）。 公司由淄博英科医疗制品有限公司以整体变更方式设立，在淄博市市场监督 管理局注册登记并取得《营业执照》，统一社会信用代码：9137030068946500X7。 第三条 公司于 2017 年 6 月 23 日经中国证券监督管理委员会（以下简称 "中国证监会"）核准，首次向社会公众发行人民币普通股 2,430.9827 万股，于 第四条 公司注册名称：英科医疗科技股份有限公司 公司英文名称： INTCO MEDICAL TECHNOLOGY CO.,LTD. 第五条 公司住所：淄博市临淄区齐鲁化学工业园清田路 18 号 邮政编码：255414 第六条 公司注册资本为人民币 64,170.0369 万元。 第七条 公司为永久存续的股份有限公司。 第八条 董事 ...

Core Viewpoint - The company has established a comprehensive information disclosure system to ensure compliance with legal requirements and protect shareholders' rights, emphasizing the importance of timely, accurate, and complete information dissemination [1][2][3]. Group 1: Information Disclosure Principles - Information disclosure is a continuous responsibility of the company, which must adhere to relevant laws and regulations [2]. - The company must treat all shareholders fairly and disclose information that may significantly impact their decisions in a clear and understandable manner [3][4]. - The company is required to disclose information proactively, especially if it could materially affect shareholders and stakeholders [3][4]. Group 2: Reporting Requirements - The company must disclose periodic reports, including annual, semi-annual, and quarterly reports, within specified timeframes [5][6]. - If the company anticipates that its annual performance or financial status will significantly change, it must issue a performance forecast within one month after the fiscal year ends [6][7]. - The company must also disclose any major events or transactions that could impact its stock price or investment decisions promptly [8][9]. Group 3: Major Transactions and Related Party Transactions - Major transactions, such as asset purchases or sales, must be disclosed if they meet certain thresholds, including a 10% impact on total assets or significant revenue contributions [10][11]. - Related party transactions must also be disclosed if they exceed specified monetary thresholds, ensuring transparency in dealings with affiliated entities [12][13]. Group 4: Other Significant Events - The company must disclose any significant events that could materially affect its securities or investment decisions, including major losses, legal issues, or changes in management [14][15]. - The company is required to report any changes in its operational status or significant external factors that could impact its business [15][16]. Group 5: Information Disclosure Management - The board of directors is responsible for overseeing the information disclosure process, with the chairman being the ultimate responsible party [17][18]. - The company must maintain a structured approach to information disclosure, ensuring that all relevant personnel are informed and comply with disclosure obligations [19][20]. - The company must implement internal controls to ensure the accuracy and timeliness of financial reporting and disclosures [21][22].

英科医疗科技股份有限公司 第一章 总 则 第一条 为有效落实英科医疗科技股份有限公司（以下简称"公司"）风险管理和 流程控制，保障公司经营管理的安全，防范和化解各类风险，提高经营效益和效率， 保护投资者合法权益。根据《中华人民共和国公司法》《中华人民共和国证券法》《企 业内部控制基本规范》《深圳证券交易所创业板股票上市规则》(以下简称《创业板上市 规则》)、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等法律法规以及《英科医疗科技股份有限公司章程》（以下简称《公司章程》），制定 本制度。 第二条 本制度所称的内部控制是指公司董事会、高级管理人员及全体员工为实 现下列控制目标而提供合理保证的过程： （一）确保国家有关法律、法规和公司内部规章制度的贯彻执行； （二）提高公司经营效益和效率； （三）保障公司资产的安全、完整； （四）确保公司信息披露的真实、准确、完整、及时和公平。 第三条 公司内部控制制度应当遵循下列原则： （一）全面性原则。内部控制应当贯穿决策、执行和监督全过程，覆盖公司及其 下属企业的各种业务和事项。 （二）重要性原则。内部控制应当在全面控制的基础上，关注重要业务事 ...

General Provisions - The company establishes guidelines to enhance the role of the board secretary and ensure compliance with relevant laws and regulations [1][2] - The board secretary is a senior management position responsible for the company and the board [1][2] - The board secretary must meet qualifications set by the relevant regulations and pass a qualification exam recognized by the Shenzhen Stock Exchange [1][2] Responsibilities - The board secretary is responsible for organizing information disclosure, managing investor relations, and coordinating communication between the company and stakeholders [5][11] - The board secretary must ensure compliance with information disclosure regulations and maintain confidentiality of sensitive information [13][19] - The board secretary is tasked with preparing board and shareholder meetings, maintaining meeting records, and ensuring the quality of documents submitted for review [12][23] Employment and Termination - The company must promptly announce the appointment of the board secretary, including personal details and qualifications [2][9] - The board secretary can be dismissed for failing to fulfill duties, legal violations, or causing significant losses to the company [26][28] - In the event of a vacancy, the board must appoint an interim secretary and complete the hiring of a new secretary within three months [30][31]

英科医疗科技股份有限公司 第一条 为了进一步规范本公司董事会的议事方式和决策程序，促使董事和董事 会有效地履行其职责，提高董事会规范运作和科学决策水平，根据《中华人民共和国 公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票上市规则》《深圳 证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》《英科医疗 科技股份有限公司章程》（以下简称《公司章程》）等有关规定，特制定本规则，作 为董事会运作的行为准则。 第二条 董事会下设董事会办公室，处理董事会日常事务。 董事会秘书或证券事务代表兼任董事会办公室负责人，保管董事会和董事会办公 室印章。 第三条 董事会会议分为定期会议和临时会议。 董事会每年应当至少召开两次定期会议。 第四条 在发出召开董事会定期会议的通知前，董事会办公室应当充分征求各董 事的意见，初步形成会议提案后交董事长拟定。 董事长在拟定提案前，应当视需要征求经理和其他高级管理人员的意见。 （三）提议会议召开的时间或者时限、地点和方式； 提案内容应当属于《公司章程》规定的董事会职权范围内的事项，与提案有关的 材料应当一并提交。 第五条 有下列情形之一的，董事会应当召开临时会议： （一 ...

英科医疗科技股份有限公司 第一章 总 则 第一条 为了规范英科医疗科技股份有限公司（以下简称"公司"）对外担 保行为，防范对外担保风险，根据《中华人民共和国公司法》（以下简称《公司 法》）《中华人民共和国民法典》《深圳证券交易所创业板股票上市规则》《上 市公司监管指引第8号——上市公司资金往来、对外担保的监管要求》等法律法 规、部门规章、规范性文件以及《英科医疗科技股份有限公司章程》（以下简称 《公司章程》）的有关规定，结合公司的实际情况，制定本制度。 第二条 本制度所称"对外担保"是指公司为他人提供保证、抵押、质押或 其他形式的担保，即公司与债权人约定，当债务人不履行债务时，公司作为保证 人按照约定履行债务或承担责任。 第三条 本制度所称"对外担保"包括公司对控股子公司的担保。 公司及其控股子公司的对外担保总额，是指包括公司对控股子公司担保在内 的公司对外担保总额与控股子公司对外担保总额之和。 第四条 公司对外担保必须经董事会或者股东会审议，审议后需及时对外披 露。 第五条 公司对外担保应当遵循合法、审慎、互利、安全的原则，严格控制 担保风险。公司有权拒绝任何强令其为他人提供担保的行为。 第六条 公司对外担 ...